# A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma

> **NCT01377025** · PHASE2 · UNKNOWN · sponsor: **Prof. Dr. med. Max. E. Scheulen** · enrollment: 200 (estimated)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** Placebo
- **DRUG:** Sorafenib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01377025
- **Lead sponsor:** Prof. Dr. med. Max. E. Scheulen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-06
- **Primary completion:** 2016-06
- **Final completion:** 2017-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2014-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01377025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01377025, "A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01377025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*